Maintaining the quality of life after surgery in the radical prostatectomy patient is of paramount importance. One of the major dilemmas in surgical management of radical retropubic prostatectomy (RRP) is preservation of the neurovascular bundle and, hence, erectile function and the continence mechanism. This manuscript addresses anatomical considerations for the surgeon and discusses the following issues with regard to medical and surgical therapies: (1) incidence of erectile dysfunction solely due to complications during RRP; (2) nerve damage during RRP; (3) vascular damage during RRP; (4) current medical and surgical therapies for restoring or maintaining potency; and (5) new advances on the horizon for management of the prostatectomy patient.
Introduction
In determining the true incidence of erectile dysfunction (ED) secondary to surgical techniques for prostate cancer one needs to consider the total prevalence of ED in the age-matched population. Estimates of ED are variable, ranging from 40% in men 40 y of age to 70% in men in their seventh decade, and are associated with vascular risk factors such as cardiovascular and peripheral vascular disease, hypertension, diabetes and cigarette smoking. 1 Thus, one of the dif®culties encountered when dissecting out the incidence of ED due solely to the complications of prostate cancer surgery is the increased incidence of ED with both age and concomitant vascular disease. Furthermore, distinguishing between the patient's ability to attain and maintain an erection suf®cient for penetration and his observations that`my erection is not as hard as it used to be' complicates the assessment of ED in agematched cohorts. Incidence estimates suggest a range of ED from 43% 3 to 84% 2 following radical prostatectomy.
Despite these limitations, our goal is to understand the treatment-speci®c etiologies of ED in men undergoing both surgical and nonsurgical treatment for prostate cancer. This paper examines the different treatment modalities and discuss the possible mechanisms and incidence of ED. Sexual function is a signi®cant patientapartner and physician concern as pharmacotherapy for ED and the surgical management of radical retropubic prostatectomy (RRP) has improved. 5 
Erectile dysfunction after radical prostatectomy
One of the major dilemmas in RRP surgical management is preservation of the neurovascular bundle and, hence, the erectile functionacontinence mechanism. 1 ± 7 The surgeon should be aware of surgical anatomical relationships during dissection. Modi®cations in the surgical approach with nervesparing prostatectomy has resulted in improvement in the incidence of post-operative morbidity 3 and has decreased the incidence of ED to as low as 10% in selected patients. 6 In contrast, the perineal approach for radical prostatectomy is associated with a much higher incidence of ED. 7 
Anatomy of the pelvic plexus
In 1982, Walsh and Donker studied stillborn male neonates to determine the topographical relationship between the pelvic nerve plexus, prostate, urethra and urogenital diaphragm. 3 The pelvic plexus encompasses both parasympathetic and sympathetic ®bers which innervate the pelvic organs and external genitalia. The parasympathetic nerves provide the primary component of the autonomic nervous system. Parasympathetic visceral efferent preganglionic ®bers arise from S2 to S4. This pelvic nerve or nervi erigentes was ®rst named by Eckhard in 1863. 8 The sympathetic ®bers arise from the thoracolumbar region T11 to L2 and reach the pelvic plexus predominantly via the hypogastric nerve. The sacral sympathetic chain and branches accompanying the superior hemorrhoidal artery also contribute sympathetic ®bers. 3 The pelvic plexus innervating the rectum, bladder, prostate, seminal vesicles, urethra and corpora cavernosa is located retroperitoneally on the lateral wall of the rectum in relation to the tip of seminal vesicles and extends from the sacrum ventrally as high as the pouch of Douglas. 3, 10 The most caudal ®bers of the pelvic plexus travel along the posterolateral aspect of the prostate to innervate the corpora cavernosa. 11 The cavernous branch of the pelvic plexus travels at the posterolateral aspect of the base of the prostate. 10 Here the branches coalesce and travel together with the capsular arteries and veins (neurovascular bundle) in the lateral pelvic fascia outside the prostatic capsule and Denonvillier's fascia. 10 At the proximal prostatic urethra, the nerves are quite distant from the prostatic capsule. As the nerves approach the apex of the prostate, they are only a few millimeters away from the prostatic capsule at the 5 and 7 o'clock positions. 11 A cross section of the membranous urethra demonstrates cavernous nerve bundles at the 3 and 9 o'clock positions external to the striated sphincter muscles.
Some ®bers of the cavernous nerve penetrate the tunica albugenia of the corpus spongiosum distal to the membranous urethra. These ®bers innervate the vascular and erectile tissue of the corpus spongiosum and glans penis. Other ®bers continue outside the corpus spongiosum. At the level at which the paired crura converge, the nerve ®bers are found in the 1 and 11 o'clock positions. Some of these bundles will penetrate the corpus spongiosum individually while others travel with the deep artery and cavernous vein. After entering the corpus cavernosum the terminal branches divide and innervate the helicine arteries and central erectile tissue. 10 
Vascular anatomy
Erectile dysfunction can also result as a complication of inadvertent damage to the pelvic vascular supply during prostate surgery. The arterial supply to the penis, while variable, is classically described as three branches from the internal pudendal. The bulbourethral arteries are the ®rst branches of the internal pudendal reaching the penis, entering distal to the urogenital diaphragm. The cavernous arteries branch next and assume a central location within the corpora. The dorsal arteries represent the third branch which supplies the circum¯ex arteries and glans penis. Signi®cant variation in the blood supply to the penis was found by Breza et al in a study of adult male cadavers. 12 In their dissections they found an accessory internal pudendal artery in seven of 10 cadavers, predominantly on the left. These traveled along the lower aspect of the bladder and the anterolateral surface of the prostate to the dorsal root of the penis. The origin of the accessory pudendal artery varied among the ipsilateral obturator artery, ipsilateral inferior vesical artery and contralateral superior vesical artery. In ®ve of the patients the accessory pudendal artery constituted an additional blood supply. In one patient the accessory pudendal arteries provided the entire blood supply to the left side of the penis. One patient had bilateral accessory pudendal arteries which supplied the cavernosal artery.
Because of its proximity to the prostate and bladder, the arterial supply to the penis may be compromised during radical pelvic surgery. Reports have been published about the prevalence and variable origin of penile arterial supply, the potential dominance of the accessory pudendal arteries, and the importance of preserving penile blood¯ow during prostate surgery to the recovery of sexual function. 13 ± 18 Furthermore, it has been shown that trauma to the penile crus leading to penile vascular insuf®ciency 19 or pudendal artery occlusion 20 may lead to ED. The presence of both cavernosal arterial insuf®ciency and corporeal veno-occlusive dysfunction co-existing or independently affecting erectile function has been demonstrated following bilateral nerve RRP. 16 ± 18 If vascular insuf®ciency is present, penile rigidity suf®cient for vaginal penetration may not occur.
Prevention of nerve and vascular damage
With a knowledge of pelvic surgical anatomy, the pelvic plexus and cavernous nerves can be identi®ed peri-operatively and the feasibility of preserving these structures in an attempt to maintain potency can be considered. A decision must be made in light of tumor location and volume with efforts to spare potency without compromising tumor removal. If excision of one neurovascular bundle is required, the contralateral side can usually be preserved. The surgical technique for preservation of the neurovascular bundles is described elsewhere. 13 The correlation of ED as a consequence of nervesparing radical prostatectomy reported by Quinlan showed that 68% of men were potent postoperatively. 3 Factors associated with return of sexual function were patient age, clinical and pathologic stage and surgical technique. 13 Results corrected for age and stage showed a two-fold increase in risk of ED when one neurovascular bundle was excised.
Evaluation and treatment
The goals of evaluating patients with ED are to determine the medical and psychosexual causes, assess the degree of dysfunction, presence of comorbidities and to determine the treatment goals for both patient and partner. Although multifactorial ED is common, the duration of dysfunction, level of libido, presence of morning erections, erection quality and psychological factors can help direct further work-up and treatment. Nonsurgical approaches and pharmacotherapy, including noninvasive (oral) and minimally invasive (intraurethral suppositories and intracavernosal injections) therapies are brie¯y reviewed below.
Nonsurgical Treatments
The vacuum erection device is simple to use and inexpensive. The erection produced is unlike physiologic erection or one that is produced pharmacologically, since placing the constriction ring to potentiate the erection can result in gradual corpus ischemia. Further, a`hinge effect' may be produced because the corpus cavernosum proximal to the constriction device is not rigid. Recently, a number of investigators have used the vacuum erection device as prophylaxis for both preventing loss of erectile function and penile shortening. The constriction ring may be uncomfortable or painful and may produce bruising. Nevertheless, satisfaction rates range from 68 to 83%. 21 
Oral therapy
Oral agents for treatment of ED by virtue of their systemic administration can have both central nervous system and peripheral effects. Thus, therapy can be targeted to the adrenergic, dopaminergic and serotonergic receptors in the brain as well as the nitric oxide (NO) pathway and adrenergic or prostanoid receptors in the penile corpus cavernosum. 22 Phentolamine (Vasomax TM ) is both an alpha-1 and alpha-2 adrenergic receptor antagonist 23 that can also be used for injection therapy. There is early evidence that buccal administration may improve erectile function. Three studies have examined its use and have found a response rate of 20 ± 42%. Good response was found with psychogenic or mild vascular ED but very poor responses were reported in those with serious vascular involvement. 22, 24 Clinical trials may soon resume with this product.
Yohimbine (Yocon TM ) is an alpha-2-adrenergic antagonist obtained from the bark of the yohim tree, which has been utilized as an aphrodisiac for centuries. 22 In a recent controlled study of patients receiving 6 mg three times a day, 21% with primary organic ED had complete recovery of erections. 25 Thirteen percent of the control group also experienced a positive response; however, no statistical signi®cance was found between yohimbine and placebo. Response was statistically signi®cant in patients with psychogenic ED, as 62% of patients treated with yohimbine responded vs 16% of those in the placebo group. 25 However, a recent trial of organic ED patients showed that yohimbine was ineffective in this patient cohort. 26 Apomorphine is a dopaminergic agonist known to induce yawning, nausea and penile erections in animals and humans when injected subcutaneously. 22 A subbuccal tablet has been developed which is reportedly successful in inducing erections in patients with minimal disease. 22 Side effects include yawning, nausea, vomiting and hypotension. Studies investigating the utility of this drug are underway and Food and Drug Administration (FDA) approval is expected soon.
Trazodone (Desyrel TM ) is a 5-hydroxytryptamine receptor agonist indicated for mild depression, but this agent may also function as an alpha-adrenergic blocking agent. 27, 28 It has been shown to increase nocturnal penile tumescence episodes when administered orally and induce tumescence when injected intracorporeally. 27, 28 A recent clinical trial demonstrated limited ef®cacy in patients with psychogenic and mild organic ED. 29 Synergistic effects with yohimbine have also been reported. 30 Sildena®l citrate (Viagra TM ) is a selective inhibitor of cyclic guanosine monophosphate (cGMP), speci®cally, phosphodiesterase type 5 (PDE5), and is the ®rst FDA approved oral pharmacotherapeutic for the treatment of ED. 31, 32 During sexual stimulation, NO is released from nonadrenergic, noncholinergic (NANC) nerves in the penile corpus cavernosum. NO diffuses into the trabecular smooth muscle cells where it activates guanylate cyclase which results in increased levels of cGMP. Ultimately, smooth muscle relaxation, corporal expansion and effective veno-occlusion results. 31, 32 Two recent studies evaluated the ef®cacy of sildena®l in post-prostatectomy patients. 33, 34 In the ®rst study, the effects of bilateral nerve sparing, unilateral nerve sparing and non-nerve sparing RRP on the ef®cacy of sildena®l treatment of ED were compared. Sildena®l was ef®cacious in only the bilateral nerve sparing cohort of patients, with 80% of them having suf®cient penile rigidity for vaginal intromission. 33 In a second study of patients in a general urology practice, patients were grouped by the severity of ED using the International Index of Erectile Function (IIEF). 34 Sildena®l was least effective in patients with the most severe ED. Interestingly, RRP patients fell into the most severe group with only 40% having tumescence when treated with sildena®l. 34 Sildena®l citrate is the ®rst-line therapy in postprostatectomy patients. However, it should be understood by physician and patientapartner alike that the results may be poor depending on the extent of the nerve andaor vascular damage as described above
Injection therapy
Intracavernosal injection therapy stimulates the natural erectile process by stimulating the corporal smooth muscles to relax. The principal drugs used are papavarine, phentolamine and prostaglandin E1. 35 Papaverine, derived from the opium poppy, is thought to increase intracellular cAMP and cGMP by inhibiting cAMP and cGMP speci®c phosphodiesterases. 35 It may also block calcium channels and increases calcium ef¯ux from cells. These actions potentiate smooth muscle relaxation in the penile arterioles, sinusoids and veins. Papaverine is metabolized in the liver and has a plasma half-life of 1 ± 2 h. While the advantages of papaverine injection include its low cost and stability at room temperature, associated complications have included priapism (0 ± 35%), corporeal ®brosis (1 ± 33%) and occasional elevation in liver enzymes. 35 Phentolamine (Regitine TM ) is an alpha-1 and alpha-2 adrenergic receptor antagonist 23 with a plasma half-life of only 30 min. It causes relaxation of corporeal smooth muscle and increases blood ow but, unlike papavarine, 35 it does not increase resistance to venous out¯ow.
Prostaglandin E 1 (PGE 1 , Alprostadil TM , Caverject TM , EDEX TM ) causes smooth muscle relaxation, dilatation and inhibition of platelet aggregation. 35 ± 37 Caverject TM was the ®rst FDA approved pharmacotherapy for ED. This prostaglandin is rapidly metabolized within the trabecular smooth muscle and in studies comparing papavarine and alprostadil, alprostadil was shown to have the advantages of a higher response rate and a lower incidence of priapism and corporeal ®brosis. Disadvantages include a much higher incidence of painful erections, higher cost, and a shorter half-life if not refrigerated. An alprostadil transurethral suppository (MUSE TM ) has been studied recently in postprostatectomy patients. The overall success rate, measured as the likelihood of active treatment to lead to intercourse at home, was 40.1%. 38 There was no increased incidence of hypotension in post-prostatectomy patients, however urethral painaburning was higher. 38 Combination therapies have also been used with good success in patients with different types of ED. 35 Alprostadil (Caverject TM ) injection has also been used in nerve sparing, post-prostatectomy patients to improve the recovery rate of erectile function. 39 Montorsi et al evaluated 30 patients 6 months after prostatectomy. Half of the patients were given intracavernous injections of alprostadil three times per week for 12 weeks. Of the patients receiving injections, 67% reported recovery of spontaneous erections compared with 20% of the placebo group. The injections were felt to improve cavernous oxygenation and therefore limit hypoxia-induced tissue damage. 39, 40 This issue, however, remains controversial.
Surgery
Failure of medical therapy, patientapartner concerns regarding ED and quality of life will in¯uence surgical therapy for ameliorating ED. The use of in¯atable penile prosthetic devices provide a natural state of¯accidity and result in rigid, on-demand erections suitable for vaginal penetration. The recent re®nement of these mechanical devices has resulted in a lowered mechanical failure and higher patient satisfaction. Discussion with the patient and partner about the advantages and disadvantages will guide device selection.
The advent and availability of two piece mechanical devices has resulted in an increased popularity of these being placed post-operatively with satisfactory results and with minimal morbidity. While these devices provide patient and partner satisfaction, it is apparent that a natural erection will not be achieved.
Thus, in select patients, early return of sexual function after non-nerve sparing radical prostatectomy can be achieved. 41 While this may be a novel approach, it overlooks the availability of noninvasive and minimally invasive pharmacotherapeutics as well as assuming a complete failure rate in recovery of potency post-radical prostatectomy.
New therapies on the horizon
Recently, evidence of nerve regeneration has been described. In work conducted by Lue and colleagues, regeneration of cavernous nerves which are partially damaged is suggested as the possible cause of delayed recovery of post-prostatectomy erectile function. 42 They studied the effects of cavernous nerve transection on the NANC nervous system and erectile function of rats. NO is felt to be the main neurotransmitter in NANC nerves. Nitric oxide synthase (NOS)-positive nerve ®bers in unilateral transection were found to regenerate almost to the level of the intact side by 6 months. Bilateral transection did not result in nerve regeneration. A suggested explanation for this was the sprouting of intact nerves from the contralateral corpus caverno-sum in the unilateral neurotomy group. Thus, unilateral cavernous nerve sparing might be suf®-cient to preserve erectile function in the rat model. This is in contrast to the results of Zippe et al, who found that sildena®l citrate was only ef®cacious in bilateral nerve sparing radical prostatectomy patients. 33 Shabsigh and colleagues 43 suggest apoptosis (programmed cell death) as the cause of postprostatectomy ED andaor decrease in penile size. In a rat model of penile denervation by bilateral cavernous neurotomy, evidence of elevated gene products found in apoptotic tissues was discovered in denervated rats vs sham operated controls. This interesting study implies a molecular explanation of the mechanism of post prostatectomy ED. 43 
Conclusion
Advances in both pelvic anatomy and current concepts of the pathophysiology following RRP have led to improved surgical results. In addition, as quality of life issues necessitate medical and surgical management, the advent of oral, minimally invasive therapies and surgical therapies have resulted in increased patientapartner satisfaction rates. Further progress with outcomes research will probably establish new inroads into quality of life issues for both patient and partner.
